Quantum BioPharma (NASDAQ/CSE: QNTM) has formally launched a public whistleblower reward program, offering up to USD $7 million to any individual or entity who can provide definitive, verifiable evidence that they were asked, hired, or induced to manipulate the Company’s stock.
This initiative is directly tied to Quantum’s ongoing landmark litigation, which alleges multi-year market manipulation and seeks damages exceeding USD $700 million.
✅ Anonymous submissions are accepted
✅ Confidentiality will be protected to the fullest extent permitted by law
✅ This program does NOT replace SEC or Canadian regulatory whistleblower programs — individuals may qualify for BOTH
How to Submit Information (Direct & Confidential)
Ineligible to Apply
- Current officers, directors, or employees of Quantum BioPharma
- Government officials/regulators acting in official capacity
- Anyone who obtained information illegally or in violation of duty
- Anyone submitting false or fabricated information
Important Legal Clarification
Rewards are not guaranteed and will only be paid if the submitted information materially contributes to a final, non-appealable legal judgment or binding settlement in the Company’s favor.
Quantum will not use any information provided until compensation terms are agreed to in writing with the whistleblower.
For full program details and FAQ, visit: QuantumBioPharma.com
This statement is issued in the interest of market integrity and shareholder protection.
Disclaimer
This Reward Program is discretionary and subject to change or withdrawal at any time without notice. Reward eligibility does not depend on whether a whistleblower testifies, awards are based on the contribution and reliability of the information. Quantum Biopharma will not direct, script, or influence any witness testimony. Rewards are not payments for testimony. Payment of any reward is contingent upon legal review, Board approval, and the successful outcome of a final, non‑appealable judgment or binding settlement of ongoing or future litigation pursued by the Quantum BioPharma at trial to which the reported information materially contributes. Nothing in this FAQ creates a contractual right to payment. This program does not replace, restrict or limit rights under the U.S. Securities and Exchange Commission (SEC) Whistleblower Program or whistleblower programs operated by Canadian regulatory authorities, and individuals remain free to report directly to the SEC and Canadian regulatory authorities.